Colorectal neoplasia-specific amino acid profiles and their diagnostic potential: a systematic review.

Clin Transl OncolMar 28, 2026 (epub)
Clinical ResearchGastroenterologyOncology (Medical)Open access

Roza C M Opperman, Sofie Bosch, Eduard A Struys et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review assessed amino acid alterations in colorectal cancer (CRC) and advanced precursors, and their potential as non-invasive diagnostic biomarkers. It included 77 studies measuring amino acids in faeces, urine, serum, plasma, tissue, or saliva. Findings varied substantially across biological matrices; tissue studies more consistently reported increased amino acids in CRC. Diagnostic performance also varied widely, with reported AUCs of 0.28-0.91 and limited external validation. Few studies examined advanced adenomas, and none assessed advanced serrated polyps. The review concludes that amino acids have limited standalone diagnostic value but may contribute to multi-metabolite panels.

Key findings

  • Across 77 studies, amino acid findings were heterogeneous across matrices, while tissue studies mostly reported upregulation in CRC.
  • Reported diagnostic performance varied widely, with AUC 0.28-0.91 and limited external validation.
  • Few studies included advanced adenomas, and none assessed advanced serrated polyps.
  • The review found limited standalone diagnostic value, while noting potential to enhance multi-metabolite panels.

Why it matters

The review highlights that amino acid profiles are not yet consistent or sufficiently validated to support standalone CRC diagnosis. It also identifies gaps in evidence for advanced precursor lesions, which are important to assess when evaluating early detection biomarkers. These findings help frame amino acid testing as an area for further biomarker research rather than an established diagnostic approach.

What to keep in mind

The underlying studies were heterogeneous across biological matrices, and external validation was limited; evidence on advanced adenomas was sparse and advanced serrated polyps were not assessed.

Source

Published in Clin Transl Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.